SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Wednesday reported a loss of $4.5 million in its second quarter.

The San Diego-based company said it had a loss of 15 cents per share.

The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 20 cents per share.

The biotechnology company posted revenue of $8.8 million in the period, which fell short of Street forecasts. Six analysts surveyed by Zacks expected $9.1 million.

In the final minutes of trading on Wednesday, the company”s shares hit $3.99. A year ago, they were trading at $5.39.


This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on CNAT at

blog comments powered by Disqus